Omnia Youssef
Professor
Evaluating Immunohistochemical Expression of Junctional Adhesion Molecule - A (JAM- A) in Multiple Myeloma
Benha medical journal. • 2025
Publication Information
Authors
Zeinab I. Elshawarby, Omneya Y. Bassyoni, Mona S. El Ashry, Aya I. Ahmed, Hala A. Agina, Amira E. Soliman
Keywords
Immunohistochemical, Junctional Adhesion Molecule – A, Multiple myeloma
Journal
Benha medical journal.
Publisher
Benha University, Faculty of Medicine
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background: 1% of all cancers and about 10% of all
haematologic malignancies are multiple myeloma (MM).
In various human cancers, including multiple myeloma,
abnormal expression or deregulation of JAM-A, which
controls cell growth and differentiation, results in a more
aggressive phenotype and poor prognosis. Aim: to
evaluate the immunohistochemical expression of JAM-A
in cases of multiple myeloma and correlate its expression
with variable clinicopathological parameters to assess its
possible diagnostic and prognostic role and hence
therapeutic modalities. Material and method: This is a
selected retrospective immunohistochemical study of
JAM-A performed on 40 cases of MM. Results: There is
a statistically significant direct correlation between JAM-
A overexpression and older Age (P= .022), histological
type (immature & plasmablastic)(P=.020), diffuse pattern
of infiltration(P=.016), increased BMB
cellularity(P=.017), higher ISS Stage (P=.033), advanced
R- ISS Stage (P=.042), No Complete response(P=.008),
more Resistance to therapy (P= .032), Karyotyping result
(P=.019), short survival (P= .014). Conclusion: JAM-A overexpression might have
an important role in proliferation, invasion, progression, poor outcome of multiple
myeloma cases. So, JAM-A might have a promising value in treatment of MM.
haematologic malignancies are multiple myeloma (MM).
In various human cancers, including multiple myeloma,
abnormal expression or deregulation of JAM-A, which
controls cell growth and differentiation, results in a more
aggressive phenotype and poor prognosis. Aim: to
evaluate the immunohistochemical expression of JAM-A
in cases of multiple myeloma and correlate its expression
with variable clinicopathological parameters to assess its
possible diagnostic and prognostic role and hence
therapeutic modalities. Material and method: This is a
selected retrospective immunohistochemical study of
JAM-A performed on 40 cases of MM. Results: There is
a statistically significant direct correlation between JAM-
A overexpression and older Age (P= .022), histological
type (immature & plasmablastic)(P=.020), diffuse pattern
of infiltration(P=.016), increased BMB
cellularity(P=.017), higher ISS Stage (P=.033), advanced
R- ISS Stage (P=.042), No Complete response(P=.008),
more Resistance to therapy (P= .032), Karyotyping result
(P=.019), short survival (P= .014). Conclusion: JAM-A overexpression might have
an important role in proliferation, invasion, progression, poor outcome of multiple
myeloma cases. So, JAM-A might have a promising value in treatment of MM.